about
Neuropathologic substrates of Parkinson disease dementia.Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNINeuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.White matter hyperintensities and imaging patterns of brain ageing in the general population.Advanced brain aging: relationship with epidemiologic and genetic risk factors, and overlap with Alzheimer disease atrophy patterns.Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel.Factors affecting Aβ plasma levels and their utility as biomarkers in ADNIMemory, executive, and multidomain subtle cognitive impairment: clinical and biomarker findings.Olfactory impairment predicts cognitive decline in early Parkinson's disease.Role of brain infarcts in behavioral variant frontotemporal dementia: Clinicopathological characterization in the National Alzheimer's Coordinating Center database.Correlating Cognitive Decline with White Matter Lesion and Brain Atrophy Magnetic Resonance Imaging Measurements in Alzheimer's Disease.Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.Identifying amyloid pathology-related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study.Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementiasCan MRI screen for CSF biomarkers in neurodegenerative disease?Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging InitiativeAging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy.Improved protocol for measurement of plasma β-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patientsCSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.Comparative survey of the topographical distribution of signature molecular lesions in major neurodegenerative diseases.Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNIValidation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia SubjectsThe Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.Clinical and multimodal biomarker correlates of ADNI neuropathological findings.Relationship between APOE Genotype and Structural MRI Measures throughout Adulthood in the Study of Health in Pomerania Population-Based Cohort.A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.Genetic and neuroanatomic associations in sporadic frontotemporal lobar degeneration.Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD).CSF Apo-E levels associate with cognitive decline and MRI changesPoly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis.The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease.Metabolic network failures in Alzheimer's disease: A biochemical road map.Impaired functional default mode network in patients with mild neurological Wilson's disease.Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG).Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.Patterns of coordinated cortical remodeling during adolescence and their associations with functional specialization and evolutionary expansion.Targeted metabolomics and medication classification data from participants in the ADNI1 cohort.
P50
Q30527797-C32476E4-F937-40DB-970D-C40A37C47986Q31110973-12A0863D-CABE-4248-A221-CA40CA6C0D3BQ33559175-56ADABA6-E9AF-48A5-8651-9D3137FA52F1Q33869820-F98DEF34-7583-496A-8CB6-5A48BFFFE7B9Q34515561-DDADB804-F287-4318-A434-092FB7DB7035Q34520856-7A43AE9B-F8E9-45BA-94FE-83EDA2159AF4Q34875967-B9616283-023D-4482-9F32-0507CC715FDEQ35821382-F448993A-9B97-4734-9917-366165A1B070Q35889053-D4025C52-3F72-4515-9E1F-2EEC6936B7DAQ35938758-AFFF80E8-095C-4DEE-86E0-9F5E552A37F6Q36037592-82119B43-3002-496E-9059-5722602EFE4FQ36260136-89CAD5BB-36E5-4DF0-AD7B-A885722B6F77Q36276506-B10CD36E-D33C-4DCA-B73B-8EF894B60634Q36353787-1B76D3A9-7485-4D6A-892E-07EA677481E1Q36623399-50A9CC54-3F32-4A77-ABCF-B7E7DD5F3BDFQ36659380-CA507B06-350F-4213-AF86-47E45B8CF5D8Q36889603-83E67683-D195-4C25-BF7E-EB34CE8C2CFEQ36932383-A65DAD19-0602-4747-8BE7-8D320D40A5F1Q37066036-8D6A2087-C925-4510-A611-4557B39EE3F6Q37272860-52B4629D-7F71-4D03-B7B7-2CA4AA238E26Q37380546-6B2C8C08-561B-4542-B880-4EB04F3380E0Q37410700-86372DE1-AF20-42F3-84FC-1864DCB77141Q37412619-CD622D65-6475-462D-B566-06C534CFECDBQ37419658-89BAF39D-D8D6-459E-A75A-C205EF8131D9Q37451408-5B4BC276-2656-43E9-AC96-C2DC2AE5445FQ37451440-86286B11-535F-4F60-BF7C-93091B4EF387Q37484810-3C992FD4-AB05-40F6-B8DC-96AA64103BDCQ37500400-5711CFAA-6028-4CE5-8262-1616105CFDC9Q37600861-8E75FB09-6383-4B27-AC53-BD1FD2C4C6DBQ37652962-CE367B26-8260-4895-8A5A-05F3FA7784D3Q37678074-131E4FE5-73F2-4AD2-8448-D591259E0B38Q37705204-572C505E-B27E-48E1-BE19-9F2803375962Q38432287-66CF2872-60A8-4395-AB81-90B689C5FCC3Q38475592-97FD5740-64B8-469F-8A30-A48A76477D5DQ38877855-5F5374FF-BD7D-4D8E-97BD-4C01238E4E25Q39636773-59E89570-9355-4D61-9B54-CFE2EBD1925CQ40168762-EC540BDF-B0E2-4238-8CD0-E05E09AFA0CFQ41140682-7588AE12-1E5C-4AE8-A4E9-94CC338564A6Q41677916-A129659E-3668-430B-9DB5-2158BC3A8268Q42379364-177BCD2B-B561-45B9-9BF1-C6431800D252
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jon B Toledo
@nl
Jon B Toledo
@sl
Jon B. Toledo
@en
Jon B. Toledo
@es
type
label
Jon B Toledo
@nl
Jon B Toledo
@sl
Jon B. Toledo
@en
Jon B. Toledo
@es
altLabel
Juan B Toledo
@en
Toledo, JB
@en
prefLabel
Jon B Toledo
@nl
Jon B Toledo
@sl
Jon B. Toledo
@en
Jon B. Toledo
@es
P106
P1153
54380869300
P1960
d6BPUZgAAAAJ
P21
P31
P496
0000-0003-4366-9268